Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Dermata Therapeutics ( (DRMA) ).
On July 15, 2025, Dermata Therapeutics held its Annual Meeting of Stockholders where key decisions were made, including the election of two Class I directors and the ratification of Baker Tilly US, LLP as the independent auditor for 2025. Additionally, the meeting approved the issuance of shares of common stock to comply with Nasdaq Listing Rule 5635(d), which could impact the company’s market positioning and shareholder value.
The most recent analyst rating on (DRMA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.
Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Dermata Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development of innovative dermatology treatments.
Average Trading Volume: 130,703
Technical Sentiment Signal: Sell
Current Market Cap: $4.65M
See more insights into DRMA stock on TipRanks’ Stock Analysis page.